EGFR and non-small cell lung carcinoma: Therefore, this study aimed to clarify the metabolic changes in patients’ serum after treatment with EGFR-TKIs and PD-1/PD-L1 inhibitors and identify metabolic reprogramming mechanisms, thus providing new evidence for targeted therapy and antitumor immunotherapy in NSCLC.